COVID-19 pneumonia.
Conditions
Interventions
Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (Tab hydroxychloroquine 400 mg twice daily at day 1 then 200 mg twice daily plus Tab lopinavir/ritonav
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with highly suspected diagnosis of COVID-19 Patients with confirmed diagnosis of COVID-19 Patients who are candid for hospitalization Patients who are candid for starting triple-drug combination
Exclusion criteria
Exclusion criteria: History of drug allergy Pregnancy Lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Cutaneous complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Neurological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Renal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Hematological complications. Timepoint: Daily. Method of measurement: Interview and patient's record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Clinical outcome (cure or death). Timepoint: End of treatment. Method of measurement: Patient's record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Khalili
Tehran University of Medical Sciences
Outcome results
None listed